Johnson & Johnson is set to report its earnings for the third quarter before the market opens tomorrow. Let’s look at analysts’ expectations for the third quarter.
When is JNJ’s earnings date?
Johnson & Johnson is slated to report its third-quarter earnings results on Oct. 13 before the market opens. The company has scheduled a conference call on the same day, at 8:30 a.m. ET. In the third quarter, analysts expect Johnson & Johnson to report revenue of $20.1 billion, which would be 3 percent lower than JNJ's $20.7 billion in revenue in the third quarter of 2019. Analysts expect the company to report adjusted EPS of $1.96 in the third quarter, which represents a significant fall year-over-year from $2.12.
What is Johnson & Johnson’s COVID-19 vaccine?
Currently, Johnson & Johnson is developing and testing Janssen’s experimental coronavirus vaccine candidate, JNJ-78436735, which is in Phase 3 of its clinical trials. Johnson & Johnson is the fourth company to enter the final stage of testing a COVID-19 vaccine candidate in the U.S. The others are Moderna, AstraZeneca, and Pfizer.
The U.S. Department of Health and Human Services said it would pay Johnson & Johnson approximately $1 billion to produce and deliver 100 million doses of its experimental COVID-19 vaccine, with the option to buy 200 million additional doses.
What is JNJ’s stock price? What is JNJ’s stock price in premarket trading today?
JNJ stock was up about 0.5 percent at $151.69 in premarket trading today as of 5:26 a.m. ET. The stock rose 1.4 percent on Oct. 9 and closed at $150.97 with a market capitalization of $397.5 billion. JNJ stock has risen by 1.9 percent in the last five days and 15.5 percent in the last year. The stock is trading 3.8 percent below its 52-week high of $157 and 38.3 percent above its 52-week low of $109.16.
What is JNJ’s dividend yield?
As of Oct. 9, JNJ’s dividend yield was 2.68 percent. The company currently pays an annual dividend of $4.04 per share.
What is JNJ’s stock forecast?
Currently, analysts' stock price forecast for JNJ is $164.59, which suggests a 9.0 percent upside. Their highest target price of $180 implies a 19.2 percent upside, while their lowest target price of $142 suggests a 5.9 percent downside. Of the 23 Wall Street analysts tracking JNJ, 12 recommend "buy," eight recommend "hold," and three recommend "sell."
JNJ investor relations
JNJ plans to hold its third-quarter earnings conference call on Oct. 13 at 8:30 a.m. ET. Investors can access the earnings conference call on the company’s investor relations page.